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New derivatives of sulfonylhydrazone as potential antitumor 
agents: Design, synthesis and cheminformatics evaluation
Phosphoinositide 3-kinase α (PI3Kα) is a propitious target 
for designing anticancer drugs. A series of new N’-
(diphenylmethylene)benzenesulfonohydrazide was synthe-
sized and characterized using FT-IR, NMR (1H and 13C), 
HRMS, and elemental analysis. Target compounds exhibi-
ted an antiproliferative effect against the human colon carci-
noma (HCT-116) cell line. Our cheminformatics analysis 
indicated that the para-tailored derivatives [p-NO2 (3) and 
p-CF3 (7)] have better ionization potentials based on calcu-
lated Moran autocorrelations and ionization potentials. 
Subsequent in vitro cell proliferation assays validated our 
cheminformatics results by providing experimental evi-
dence that both derivatives 3 and 7 exhibited improved 
antiproliferative activities against HCT-116. Hence, our 
 results emphasized the importance of electron-withdraw-
ing groups and hydrogen bond-acceptors in the rational 
design of small-molecule chemical ligands targeting PI3Kα. 
These results agreed with the induced-fit docking against 
PI3Kα, highlighting the role of p-substituted aromatic rings 
in guiding the ligand-PI3Kα complex formation, by target-
ing a hydrophobic pocket in the ligand-binding site and 
forming π-stacking interactions with a nearby tryptophan 
residue.
Keywords: sulfonylhydrazones, antitumor, HCT-116, PI3Kα- 
-inhibitors, cheminformatics, docking
Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that incite the phosphoryla-
tion of the inositol ring of phosphatidylinositol 4,5-biphosphate (PIP2) creating 3,4,5-tri-
phosphate (PIP3) (1, 2). PIP3 invokes downstream signaling components like protein kinase 
B (AKT) (2). The intracellular amount of PIP3 is down-regulated by phosphatase and tensin 
homolog protein (PTEN) (3, 4). PI3Ks signaling pathway moderates cell growth, differen-
tiation, migration, metastasis, invasion and angiogenesis (2).
Three classes of PI3Ks have been identified according to their sequences and sub-
strates selectivity. Class IA PI3Ks harbors PI3Kα, β, and δ isozymes (5). Aberrant PI3Kα/
AKT trafficking cascade has been observed in numerous human tumors (2).
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PI3Kα gene (PIK3CA) is amplified, up-regulated and mutated in diverse human can-
cers (5–7). Prevalent PIK3CA mutations in the helical (E545K and E542K) and kinase 
(H1047R) domains are detected in colon, brain, breast and endometrial cancers (8–10). 
PIK3CA alterations change PI3Kα structure and incite the in vitro kinase activity (6, 7, 11, 
12).
Therefore, the design and development of selective mutant PI3Kα inhibitor is a promi sing 
scenario for cancer treatment (12, 13). The high frequency of PI3Kα and PTEN mutations 
shed the light on the significance of PI3Kα as a hot target for designing and developing 
anticancer drugs (14, 15). Diverse chemical core structures have been designed and synthe-
sized targeting PI3Kα inhibition (16–22) and some of them have been explored in human 
observational studies (23–25).
Employing a pharmacophore-based drug design approach of active PI3Kα inhibitors 
and screening against the National Cancer Institute (NCI) (26) database with 265,242 com-
pounds, we identified 2-(2-hydroxy-4-methoxybenzoyl) benzoic acid (NSC 79888) as a hit 
(27) (Fig. 1).
Fortunately, a structural analogue of NSC 79888, 1-(diphenylmethylene) hydrazine, is 
available commercially and it bears the fingerprint of PI3Kα active inhibitors (Fig. 2). 
 Accordingly, we have hypothesized that tailoring the core structure of 1-(diphenylmethylene) 
hydrazine might generate potential PI3Kα inhibitors.
Recently, we functionalized the scaffold of benzoin (NSC 8082), targeting PI3Kα inhi-
bition, creating 2-oxo-1,2-diphenylethyl substituted benzoates (28) and phenyl imino-1,2- 
-diphenylethanol derivatives (21). The 2-oxo-1,2-diphenylethyl benzoate series exerted an 
inhibitory activity against human colon carcinoma (HCT-116) cell line with IC50 of 0.73–2.82 
mmol L–1 and it induced apoptosis (28). However, the phenylimino-1,2-diphenylethanol 
 derivatives exhibited selective antiproliferative activity against breast adenocarcinoma 
(MCF-7), breast carcinoma (T47D), and HCT-116 cell lines as well as they incited apoptosis 
and inhibited angiogenesis (21). Additionally, we tailored the core structure of p-anisoin, 
as a PI3Kα inhibitor, forming a library of 1,2-bis(4-methoxyphenyl)-2-oxoethyl benzoates 
(22). Derivatives of 1,2-bis(4-methoxyphenyl)-2-oxoethyl benzoates showed selective 
 suppressive activity against MCF-7, T47D and HCT-116 cell lines (22). Modeling studies 
displayed that the scaffold is engaged in PI3Kα and/or ERα binding site. Recently, Younus 










2-(2-Hydroxy-4-methoxybenzoyl) benzoic acid 
(NSC 79888)
1-(Diphenylmethylene) hydrazine Benzoin (NSC 8082), R = H
p-anisoin, R = -OCH3
Fig. 1. Structures of compounds 2-(2-hydroxy-4-methoxybenzoyl) benzoic acid (NSC 79888), 1-(diphenyl - 
methylene) hydrazine, benzoin (NSC 8082) and p-anisoin. 
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In this work, we tailored the amino moiety of 1-(diphenylmethylene) hydrazine to 
investigate the effect of introducing benzenesulfonohydrazide motif on the occupation of 
PI3Kα kinase cleft, ligand/PI3Kα binding, and cytotoxic activity. A scaffold of N’-
(diphenylmethylene)-substituted benzenesulfonohydrazides was outlined to fit the phar-
macophore of PI3Kα inhibitors and exemplified in NSC 79888 (Fig. 3).
Fig. 2. Pharmacophore model of: a) NSC 79888 and b) 1-(diphenylmethylene) hydrazine. Pictures vi-
sualized by MOE (58).
Fig. 3. Pharmacophore model with compound 1 (C atoms in grey, Aro – aromatic rings, Acc – H-bond 
acceptor, Hyd – hydrophobic groups). Picture captured by MOE (58).
a)                                                                       b)
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The derivatives were synthesized to probe the significance of attaching substituted 
benzenesulfonohydrazide motif to explore the structure-activity relationship (SAR) and 
optimize their inhibitory activity as anticancer compounds. Consequently, this work deli-
neates the design and synthesis of N’-(diphenylmethylene)-benzenesulfonohydrazides 
recruiting molecular docking studies. Biological evaluation of prospective compounds 




All solvents and chemicals were bought from Acros Organics (USA), Sigma-Aldrich 
(USA), Fluka (Switzerland), Tedia (USA), and Fisher Scientific (USA). Chemicals and sol-
vents were manipulated as delivered and without additional purification: benzophenone 
hydrazone, 2-chlorobenzenesulfonyl chloride, 2-nitrobenzene sulfonyl chloride, 3-nitro-
benzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride, 2-flurobenzene sulfonyl chlo-
ride, 3-flurobenzenesulfonyl chloride, and 4-trifluromethyl benzene sulfonyl chloride.
Melting points were recorded using a Gallenkamp melting point apparatus (Gemini 
Lab, The Netherlands) and are uncorrected. Infrared (IR) spectra were measured as KBr 
discs using Shimadzu IR Affinity FTIR spectrophotometer (Shimadzu, Japan). 1H and 13C 
NMR spectra were documented using Bruker, Avance DPX-500 spectrometer (Bruker, 
USA). Chemical shifts are given in (ppm) using TMS as a reference. High-resolution mass 
spectra (HRMS) were acquired with the aid of a Bruker APEX-IV (7 Tesla) instrument 
(Bruker). External calibration was carried out by an arginine cluster at a mass range of m/z 
175–871, and the samples were got in a solution using chloroform. Elemental analyses were 
recorded using a EuroVector (Italy) elemental analyzer, model EUROEA3000 A.
Thin-layer chromatography (TLC) was developed on aluminum cards (20 × 20 cm, 
layer thickness 0.2 mm), pre-coated with fluorescent silica gel GF254 DC-alufolien-Kieselgel 
(Fluka Analytical, Germany) and visualized by UV light application at 254 and 360 nm. 
The mobile phase was cyclohexane/ethyl acetate (9:1).
Synthesis of N’-(diphenylmethylene)-substituted benzenesulfonohydrazides (1–7)
General procedure. – Compounds 1–7 were synthesized according to the following pro-
cedure: a mixture of benzophenone hydrazone (1.45 g, 8 mmol) in 20 mL methanol was 
introduced to an agitated suspension of substituted benzenesulfonyl chloride (1.72 g, 10 
mmol) in 40 mL methanol. Then, 0.5 mL concentrated HCl was added to the reaction mix-
ture and the resulting solution was refluxed for 3 h. The mixture was cooled to 0 °C and 
the residue was harvested using suction filtration, cleansed with methanol and dried 
 under reduced pressure to collect the desired product. The obtained compounds were: 
N’-(diphenylmethylene)-2-nitrobenzenesulfonohydrazide (1), N’-(diphenylmethylene)- 
-3-nitrobenzenesulfonohydrazide (2), N’-(diphenylmethylene)-4-nitrobenzene-sulfono-
hydrazide (3), N’-(diphenylmethylene)-2-fluorobenzenesulfonohydrazide (4), N’-(diphenyl 
methylene)-3-fluorobenzenesulfonohydrazide (5), N’-(diphenylmethylene)-2-chloroben-
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zene sulfono-hydrazide (6), and N’-(diphenylmethylene)-4-(trifluoromethyl)benzenesul-
fonohydrazide (7).
The physicochemical properties and spectral data of compounds 1–7 are given in 
 Tables I and II.
Biological testing
In vitro cell proliferation (MTT) assay. – The antiproliferative effect of promising deri-
vatives was detected using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) test (Promega, USA). The test probes cell viability by measuring the capability of 
cells to reduce MTT to blue material through the activity of mitochondrial dehydrogenase 
(30).
Actively dividing HCT-116 cells (ATCC, Manassas, VA, USA) were generously pro-
vided by the University of Jordan (Amman, Jordan). Cells were collected, washed and 
dispersed in RPMI 1640 tissue culture medium. Cell viability was tested using the trypan 
blue staining. Cells were adhered at a density of 15,000 cells per well into 96-well tissue 
culture flat-bottom plates and incubated for 24 h. Incubated cells were dissolved in DMSO 
and tested three times with increasing concentrations (0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25 and 
50 mmol L–1) of each compound for 48 h, and change in MTT color was measured using a 
microplate reader (Biotek, USA) at 595 nm (31). Results are presented in Table III.
Identification of VEGF expression in HCT-116 cells. – The level of VEGF in HCT-116 cells ino-
culated with compound 7 was assessed by VEGF enzyme-linked immunosorbent assay 
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(ELISA) kit (Sigma, USA). HCT-116 cells were prepared in small flasks at a density of 1.5x105 
and subjected to one of the mentioned treatments for 48 h: compound 7 (3 mmol L–1), LY-
294002 (10 µmol L–1), negative control (0.1 % DMSO). The concentration of compound 7 was 
selected to be close to its IC50 value (2.5 mmol L–1) and the concentration of LY-294002 was 
obtained from the previous studies on the same cell line (32). After inoculation, cells were 
detached using lysis buffer followed by centrifugation. Supernatants were harvested and 
distributed in 96-well microplates coated with anti-VEGF antibody. Biotinylated detection 
antibodies were added and incubated for 2.5 h. The last step involved the addition of HRP-
conjugated streptavidin followed by 3,3’,5,5’-tetramethylbenzidine substrate solution with 
30-min treatment in dark for color development. Color intensity was measured at 450 nm (32).
Determination of caspase-3 activity. – The level of inducing apoptosis was detected by 
the caspase-3 activity kit (Abcam, USA). HCT-116 cells were cultured as previously descri bed 
and exposed to the same treatments as mentioned in the VEGF section. Caspase-3 activity 
was measured in treated cells following the kit protocol.
Real-time PCR. – Freshly cultured HCT-116 cells were seeded in 96-well plates at a 
density of 15,000 cells per well and inoculated for 48 h with 1–7 (3 mmol L–1), LY-294002 
[2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride, 10 µmol L–1] and 
negative control (0.1 % DMSO). Total RNA for all treatments was extracted by SV total 
RNA isolation system (Promega, USA) and RNA amount was quantified at 260/280 nm 
(Quawell NanoDrop, USA).
For cDNA synthesis, 1000 ng of RNA was applied in a 20 µL-reaction volume employ-
ing SCRIPT cDNA synthesis kit, Jena Bioscience (Germany). Non-specified hexamer primers 
were applied for reverse transcription and real-time PCR was conducted using the 5x HOT 
FIREPol EvaGreen qPCR Supermix, Solis BioDyne (Estonia) (33). The amplification 
 reactions were performed using Prime Pro 48 Realtime qPCR (Techne, UK) according to 
the detailed reaction conditions given in Table IV. The primers displayed in Table V were 
used to amplify target genes and dissociation curve analysis of amplification products was 
created to confirm single PCR product amplification.
Table III. PI3Kα inhibitory activity expressed as IC50
Compd. IC50 (mmol L–1)a
1 13.1 ± 1.21
2 7.9 ± 0.23
3 5.2 ± 0.88
4 12.7 ± 0.95
5 25.4 ± 1.15
6 5.4 ± 0.22
7 2.5 ± 0.09
LY294002 60.0 ± 0.09
a Mean ± SEM, n = 3.
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Computational methods
Preparation of protein ensemble. – The crystal ensemble of unbound PI3Kα (PDB ID: 
2RD0) (5) was obtained from the RCSB Protein Data Bank. The homology modeled coordi-
nate of 2RD0 was employed for this study (34). Wortmannin template in 3HHM (35) was 
conveyed to 2RD0 and defined as the ligand. Energy minimization of the side-chains was 
employed to minimize the steric clashes by MacroModel (36) panel in MAESTRO. Addi-
tional treatment of the ensemble was accomplished by Protein preparation (36) platform 
in Schrödinger software to augment H-bonding between amino acids’ backbones.
Preparation of ligand structures. – The prospective derivatives (ligands) were depicted 
using wortmannin’s template in 3HHM. The ligands were drawn using MAESTRO (36) 
build wizard and energetically relaxed by an OPLS2005 force field in MacroModel panel.
Induced-fit docking (IFD)(36). – The co-crystallized ligand wortmannin was tagged as a 
centroid in the kinase domain of 2RD0. The van der Waals scaling factors for receptor and 
ligand were calibrated to 0.5 to furnish adequate relaxation for the top docked ligand con-
formation. Extra parameters were set as default. The ligand orientation with the most 
negative XP Glide score was assigned.
Cheminformatics analysis. – All molecules were treated corresponding to the protocols 
reported by Hajjo et al. (37). Next, 2D molecular descriptors from Kode cheminformatics 
(38) were generated for all seven sulfonylhydrazone derivatives described herein, plus 
Table IV. The qPCR standard reaction conditions
Cycle step Temp. (°C) Time (s) Cycles




Table V. Primers used in the qPCR experiment





BAX GCTGGACATTGGAC TTCCTC CTCAGCCCATCTTCTTCCAG
Bcl-2 ATGTGTGTGGAGAGCGTCAACC TGAGCAGAGTCTTCAGAGACAGCC
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 PI-103 and LY-294002 as reference compounds to compare with. Molecular properties with 
absent constant and zero values were dropped off from the analysis.
Similarity searching. – A simple similarity searching in the STRING database (39) was 
conducted using the molecular structure of 7 as a query to identify ‘structurally’ similar 
compounds and identify their protein-interacting partners. STRING is a biology systems 
database that combines data about chemical interactions with crystal structures, genes 
and proteins from metabolic pathways, drug-target relationships and binding experi-
ments. Compound 7 was represented in a SMILES format to query the STRING database. 
MACCS keys calculated for 7 and database compounds were compared using Tanimoto 
coefficients to identify similar compounds. A chemical-gene(protein) interactions search 
in the STRING database was performed using compound 7 and top-scoring similar hits 
(based on Tanimoto coefficients) as queries. All retrieved protein-protein interactions 
(PPIs) were used to derive a chemical-protein interactions hypothesis for compound 7.
Pathway enrichment. – Pathway enrichments were determined using a list of Bax, BAD, 
Bcl2, Akt1, PIK3 genes to query KEGG pathways (40) included in the STRING database. 
False discovery rates were used to prioritize and rank all enriched pathways.
Data analysis
Statistical significance was assigned using one-way analysis of variance (ANOVA) 
along with unpaired Student’s t-test with significance level at p < 0.05.
RESULTS AND DISCUSSION
Chemistry
Derivatives of N’-(diphenylmethylene)-substituted benzene sulfonohydrazides (1–7) 
have been synthesized by treating benzophenone hydrazone with diversely substituted 
benzene-sulfonyl chlorides by nucleophilic substitution using methanol as polar protic 
Scheme 1
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solvent under reflux for 3 h (Scheme 1). Substituted sulfonyl chlorides are reactive species 
(due to the presence of leaving group, -Cl) and can be readily employed with primary 
amine-containing molecules to form a sulfonamide bond. The presence of electron-with-
drawing groups (nitro, halogens) on the main moiety of substituted sulfonyl chlorides 
enhances the progress of the corresponding reaction since it may increase the electrophi-
licity of the sulfur atom. These groups can withdraw electrons from the phenyl ring 
based on the inductive effect, fluorine and chlorine atoms have higher electronegativity 
than carbon of the phenyl ring, while nitrogen atom in the nitro group carries a positive 
charge. On the other hand, the lone pair of electrons at the nitrogen atom of the hydra-
zone is not localized on the nitrogen atom (can be involved in resonance) and conse-
quently decreases its nucleophilic strength. Therefore, the acid scavenger HCl was  inserted into 
the reaction vessel as a catalyst and a reflux condition was applied to overcome such 
difficulties. Methanol was selected as a solvent since it can dissolve both reactants which 
permits the reaction to proceed further. Observing the reaction progression was accom-
plished using TLC; the absence of the spot of benzophenone hydrazone (limiting reactant) 
under UV light may indicate the completeness of the reaction. Retardation factor (Rf) 
values of all products lied within the range of 0.62–0.71; in general, the Rf value between 
0.3–0.8 is required for routine TLC experiments since it indicates that the organic material 
is relatively pure and no two spots or more do overlap each other. Constitutional isomers 
of the nitro group (1–3) show closer Rf values which may be attributed to the relatively 
large size of the final products, which, consequently, minimizes the effect of different 
positions of the nitro group.
The identity of the synthesized compounds has been confirmed using various tech-
niques such as: NMR, HRMS, IR and elemental analysis (Table II). These data are in accord 
with the defined structures. Concerning NMR data, all signals are observed in the range 
of the aromatic region (6.5–8.5 ppm) for 1H NMR and from 120–150 ppm for 13C NMR; 
values of coupling constants (J) are within expected ranges for ortho-protons (8–10 Hz). The 
signal of N–H was not observed in 1H NMR spectra due to the rapid proton exchange with 
CD3OD. The chemical shift of carbon of C=N is resonated at about 155 ppm in the target 
products. It is clear that there are no significant differences in chemical shifts of each 
 proton and carbon among constitutional isomers of products that have a nitro group (1–3) 
or fluorine atom (4–5).
Furthermore, the mass spectra of verified derivatives confirm the precise molecular 
ion peaks for which the measured high resolution (HRMS) data are in agreement with the 
calculated values, based on the positive mode (by adding one extra hydrogen atom). 
 Products that contain two nitrogen atoms (4–7) showed even molar masses while those 
with three nitrogen atoms (1–3) exhibited odd molar masses in the consistency to the 
 nitrogen rule. Compound 6 shows two main peaks (M+ and M+2+) and this is due to the 
presence of the chlorine atom (isotope effect); this trend was not observed when fluorine 
was present in compounds 4, 5 and 7. No peaks for the fragmentation ions were detected 
in the employed high-resolution mass spectrometer.
Regarding IR data, no two IR bands were detected at about 3400 cm–1 which indicates 
that no primary amino group is present in the target products 1–7, instead, one band is 
observed in that region which belongs to N–H functional group. It is interesting to note 
that the absence of such two synchronous IR bands assures that benzophenone hydrazone 
(reactant) is not present in the products. In addition, the IR band of the C=N group is 
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 observed at about 1560 cm–1. The presence of phenyl rings in the products (1–7) is clear in 
IR data due to the presence of IR bands at 1440–1560 cm–1. Derivatives of sulfonyl chloride 
(reactants) usually exhibit two synchronous strong bands at about 1490 and 1190 cm–1 but 
no such bands were observed in IR spectra of products 1–7.
Elemental analyses (Table I) assure the purity of the target products in which calcu-
lated and experimental values for C, H, N are within the accepted ranges. Carbon content 
in the target products is high and ranged from about 58–64 %; this is expected due to the 
presence of three phenyl rings. It is worth noting that each sample should be well dried 
prior to the analysis to avoid any error in the measurements, in particular, for hydrogen 
element (low content ~4 %).
Biological activity
Screening against human colon carcinoma (HCT-116) cell line demonstrated that com-
pounds 1–7 exhibited a suppressive action encoding PI3Kα (Table III).
The malignant human colon carcinoma cell line (HCT-116) expresses the wild-type 
(WT) and mutant (MUT) (H1047R) PI3Kα and it was generated from an original tumor 
through biological procedures (41). Our results uncovered promising antiproliferative 
 activities of designed compounds 3 and 7 bearing p-NO2 and p-CF3 moieties consequently. 
Further analysis revealed that the presence of electron-withdrawing groups or hydrogen 
bond-acceptors on the p-position affects the electrostatic properties of the aromatic ring 
required for guiding ligand-PI3Kα interactions in the binding pocket. On the contrary, the 
inhibitory activity of o-Cl (6) indicates that hydrophobic force guides ligand/PI3Kα engage-
ment. Additionally, the antiproliferative activity of o-NO2 (1) and o-F (4) confirms that the 
hydrophobic pocket encloses the o-substituent. Contrasting the activity of m-NO2 (2) to that 
of m-F (5) clarifies that NO2 might occupy properly the binding cleft. Though, both motifs 
provide H-bond interaction; the steric effect improves the binding affinity.
Further biological testing of the most active compound (7) revealed its potential as an 
angiogenesis inhibiting agent. Angiogenesis is an essential process for cancer survival; 
vascular endothelial growth factor (VEGF) is one of the main proteins that start the angio-
genesis process (33). Treating HCT-116 cells with 7 at a concentration of 3 mmol L–1 gener-
ated a significant (p ˂ 0.05) reduction in the levels of VEGF vs. the negative control (0.1 % 
DMSO) (Fig. 4). Our results agree with reported studies that demonstrated a decrease in 
VEGF level after treating cells with PI3K/AKT/mTOR pathway inhibitors (42). Apoptosis 
(programmed cell death) induction is a complex process involving activation and inhibi-
tion of different mediator molecules. Caspases are among these mediators and their activa-
tion stimulates the process of apoptosis and cell death (43). In our study, compound 7 
generated a considerable increase in caspase-3 activity compared with the negative  control. 
A similar increase was also noticed in cells inoculated with the positive control (LY-294002) 
(Fig. 5).
Moreover, the qPCR technique was accomplished to test the effect of 7 on genes’ 
 expression involved in the apoptosis process. Treating cells with 7 (3 mmol L–1) caused a 
decrease in the expression levels of PI3K and AKT (Fig. 6). Also, it induced the pre-apop-
totic genes’ encryption (BAX and BAD) and inhibited anti-apoptotic gene (BCL2) expres-
sion.
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Computational studies
To identify the anticancer activity of the compounds 1–7 in the human colon carcinoma 
(HCT-116) cell line, we recruited the coordinates of PI3Kα (PDB ID: 2RD0) (5) to  explore the 
binding interaction of this series of compounds in PI3Kα binding site. 2RD0 binding site 
Fig. 5. Relative RNA expression of target genes in HCT-116 cells inoculated with compound 7 (3 mmol 
L–1), LY-294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride, 10 µmol L–1), for 
48 h, and negative control. Results are represented as mean ± SEM (n = 3). Significant difference com-
pared with the control: *p < 0.05.
Fig. 4. The evaluation of antitumor effects of tested compounds after inoculation with compound 7 
(3 mmol L–1), LY-294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride, 10 µmol 
L–1), and negative control. a) Vascular endothelial growth factor (VEGF) in HCT-116 cells, b) caspase-3 
activity in HCT-116 cells (folds increase was calculated by dividing caspase-3 activity of the treatment 
by the activity of the negative control). Results represented as mean ± SEM (n = 3). Significant differ-
ence compared with the control: * p < 0.05.
a)                                                                               b)
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Fig. 6. Molecular modeling using docking and pharmacophore models. The kinase site: a) 2RD0 
 accommodates the IF docked poses of 1–7 and b) superposition of the IF docked conformation of 7 
(depicted in yellow color) and the bound ligand (wortmannin) (green color). Some of the significant 
binding amino acids are shown and H atoms are unseen for clarity purpose. Picture visualized by 
PYMOL. c) The IFD X6K orientation and its original geometry in 4L23. The native template is sketched 
in red color and the docked pose is yellow-colored. Picture visualized by PYMOL. d) PI3Kα inhibi-
tors’ pharmacophore model with 1 (blue color), 3 (red color) and 6 (pink color).
a)                                                               b)
c)                                                               d)
harbors Met772, Lys776, Trp780, Ile800, Lys802, Leu807, Asp810, Tyr836, Ile848, Glu849, 
Val850, Val851, Ser854, Thr856, Gln859, Met922, Phe930, Ile932, and Asp933. The polar and 
hydrophobic linings occupy the kinase cleft. Additionally, the surface area  (polar and non-
polar) of the bound ligand accords with nearby residues. The polar backbones furnish di-
pole-dipole, ion-dipole and H-bonding. The polar basic or acidic amino acids provide an 
electrostatic (ionic) bonding. The non-polar backbone like hydrophobic and aromatic residue 
mediates hydrophobic (van der Waals) and aromatic (π-stacking) engagement, resp.
To generate a highly accurate ligand-protein complex structure we performed an in-
duced fit docking (IFD) study against the kinase domain of PI3Kα using PDB structure 
2RD0. The generated model was then used to predict the binding poses of ligands 1–7, 
postulating the structural basis for ligand-PI3Kα interactions. Our IFD results demon-
strate that 1–7 occupy the PI3Kα kinase cleft (Fig. 6a). Actually, the docked pose of 7 over-
lays that of the bound ligand conformation (Fig. 6b). The IFD approach probes the geo-
metry changes in proteins in particular; ligands are oriented to PI3Kα binding site 
recruiting Glide docking (36, 44, 45) and the highest ligand geometries are minimized 
along with protein binding site employing the Prime wizard (36). Then, a re-docking 
 protocol is recruited against the relaxed coordinates.
The backbones of the synthesized molecules engage with the backbones of Ser774 and 
Lys802 through H-bond (Table VI and Supplementary Figs. S1-S3). It’s worth noting that 
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hydrophobic (van der Waals) and aromatic (π-stacking) bonding predominates ligand/
PI3Kα complex formation. Actually, other computational (20, 28, 34, 46) and investiga-
tional studies (5) underlined the significance of these amino acids in ligand engagement.
Fig. 7. Heatmap visualization of the hierarchical clustering results of synthesized compounds and 
known PI3Kα inhibitors using Euclidean distances and complete linkages. Matrix red/blue cells 
stand for positive/negative values, resp.
Table VI. IFD scores and H-bonding








LY294002 –9.79 Y836, V851, D933
LY294002 – 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride; NA – not available
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The docking study shows that 1–7 exhibited comparable binding energy in the PI3Kα 
kinase site. The binding scores against PI3Kα predict that this scaffold might be a possible 
PI3Kα inhibitor. The more negative the binding scores of 1–7 against PI3Kα anticipate that 
this series might exert an encouraging inhibitory activity against PI3Kα. Very small nega-
tive docking scores of 1–7, against PI3Kα, suggest that these compounds are promising 
putative inhibitors for this enzyme.
To assess the accomplishment of the IFD program, we contrasted the docked geometry 
of X6K in PI3Kα (PDB ID: 4L23) (47) to its original orientation in the crystal structure. Fig. 
6c showed the overlaying of the IFD-produced X6K geometry and the original orientation 
Fig. 8. Similarity searching and network analysis. a) Top three scoring chemical hits obtained from 
similarity searching in STRING database using Tanimoto coefficient (Tc) (50) as a distance metric and 
compound 7 as a query. b) A schematic presentation of the proposed network of functional inter-
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in 4L23. The heavy atoms (all atoms except H) RMSD of X6K between the IFD-produced 
docked pose and the original pose was 0.126 Å. This declares that IFD is able to generate 
the original pose in the crystal coordinates and can consistently anticipate the ligand in-
teraction geometry.
In order to investigate the tailored functionalities of 1–7, we mapped them against a 
reported pharmacophore model of active PI3Kα inhibitors (27). The backbone of 1–7 fit the 
structural features of active PI3Kα inhibitors (Fig. 6d), represented as F1 indicating one 
aromatic ring, F2 H-bond acceptor or one aromatic ring; F3 H-bond acceptor or one aro-
matic ring or hydrophobic motif, and each (F4) or (F5) one H-bond acceptor. This finding 
rationalizes the propensity of the dataset against PI3Kα kinase cleft. Furthermore, the 
accommodation of 1–7 in the kinase domain provides an explanation for their PI3Kα 
antiproli ferative activity.
Cheminformatics analysis of the seven sulfonylhydrazone compounds in addition to 
two known PI3Kα inhibitors LY-294002 (non-selective PI3Kα inhibitor) and PI-103 (selec-
tive PI3Kα inhibitor) was performed to determine whether our compounds have diverse 
drug-like properties and if there are any similar compounds published in public chemoge-
nomics databases. Analysis results indicated that our compounds differ in their drug- 
-likeness based on Alva 2D drug-like indices and Euclidean indices. Compounds 6 and 7 
have distinct drug-like properties from the rest of the synthesized benzenesulfonohydra-
zide compounds (Fig. 7). Results also showed that that PI-103 and LY-294002 have drug-like 
properties distant from our synthesized compounds.
In order to understand the meaning of these differences in drug-likeness, we evalu-
ated correlated Alva’s drug-like indices that showed variation across synthesized com-
pounds. This analysis revealed that there is a great correlation between drug-like indices 
such as Neoplastic-80, Inflammat-80 and Hypertens-80, indicating that the introduced 
structural changes on benzenesulfonohydrazide derivatives have comparable  effects on 
calculated (i.e., predicted) drug-like properties, which predicts that our compounds might 
have anti-inflammatory and antihypertensive properties.
Additionally, a thorough analysis of 330 2D Alva descriptors that showed variation in 
their values between synthesized compounds, highlighted MATS descriptors (Moran 
 autocorrelation) as possible contributors for these drug-like differences between synthe-
sized compounds.
Three descriptors belonging to Moran autocorrelations weighted by ionization poten-
tials, namely MATS2i, MATS6i, and MATS8i differentiated between compound 7 (p-CF3 
derivative), and to a lower extent between compound 3 (p-NO2 derivative), and the rest of 
sulfonylhydrazone analogs. These findings were validated experimentally in biological 
assays where the p-CF3 (7) and the p-NO2 (3) showed improved growth inhibition of the 
HCT-116 cell line. These results confirmed that unique molecular ionization properties of 
the p-NO2 (6c) and p-CF3 (7) compounds, reflected in three calculated MATS descriptors 
mentioned above, conferred improved growth inhibition behavior in the HTC-116 cancer 
cell line. We also found evidence in the biomedical literature showing that ionization sites 
in drug molecules determine the pKa values of these drugs at specific pH, and conse-
quently, the resulting pKa values of the drugs will influence many properties, including 
dissolution rate, solubility, formulation, reaction kinetics, cell permeability, receptor inter-
actions, and protein binding (48).
Similarity searching in the STRING database was performed using 2D circular finger-
prints FCFP (49) as molecular descriptors and Tanimoto coefficient (Tc) (50) as a distance 
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metric. Results indicated that the top three most similar structural hits to 7 in the STRING 
database, i.e., compounds that have the highest Tc values, based on the presence or absence 
of molecular fingerprints that represent 7, are: N’-benzylidene-p-toluene-sulfonohydrazide 
(Tc – 0.77), pentafluorobenzaldehyde tosylhydrazone (Tc – 0.66) and benzothiadiazine 
 dioxide (Tc – 0.65) (Fig. 8a). This analysis also showed that compound 7 has a unique 
 descriptor profile for MATS6i, MATS2i and MATS8i but the rest of the pheynylhydrazone 
analogs. However, the only hit that had annotated protein connections in STRING is the 
benzothiadiazine dioxide (Tc – 0.65). There is evidence in the biomedical literature that 
benzothiadiazine-1,1-dioxides are promising therapeutic options for human malignancies 
(50, 51) and human cytomegalovirus (HCMV) infections (52). Some derivatives are positive 
allosteric modulators of AMPA receptors (53) and others are considered ionotropic 
 glutamate receptor ligands.
Pathway enrichment results using genes regulated by our compounds as query genes 
(Fig. 8b) led to the prioritization of several important biological pathways that might contrib-
ute in the process of antiproliferative activity of our lead compound 7 (supplementary tables 
SI and SII). Solid tumor pathways such as pancreatic cancer, prostate cancer, gastric cancer, 
colorectal cancer, hepatocellular and endometrial cancer, were among the top 20 most statis-
tically significant pathways, indicating that our compounds could be valuable anticancer 
agents for solid tumors. All enriched pathways were sorted according to their false discov-
ery rates (FDRs) calculated using the Benjamini and Hochberg method (55), to correct the 
enrichment p-values for multiple testing. All p-values were calculated using the hypergeo-
metric test (56). All details about STRING interaction networks can be found in ref. 57.
CONCLUSIONS
The phosphatidylinositol 3-kinase (PI3Kα) has been promoted as a hot receptor for the 
antitumor drug design. In this work, a new series of N’-(diphenyl methylene) benzene 
sulfonohydrazides was designed and developed as promising PI3Kα inhibitors. Biological 
investigation in the HCT-116 cell line displayed that the series inhibits PI3Kα activity. 
Cheminformatics analyses showed that the p-tailored analogues [p-NO2 (3) and p-CF3 (7)] 
have better ionization potentials than the rest of synthesized molecules (1, 2, 4, 5 and 6) 
expressed by calculated Moran autocorrelations. Derivative incorporating o-motif (6) 
demon strates that a hydrophobic interaction includes ligand/PI3Kα engagement. Bioactivity 
of m-attachment (2) deduces that a steric effect improves the binding interaction. The 
 induced-fit docking strategies against the PI3Kα kinase site showed that the derivatives 
form H-bond with Ser774 and Lys802.
Acronyms, abbreviations, symbols. – AKT – protein kinase B, MTT – 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, MUT – mutant, PI3Ks – phosphatidylinositol 3-kinases, PIP2 
– phosphatidylinositol-4,5-biphosphate, PTEN – phosphatase and tensin homolog protein, VEGF – 
vascular endothelial growth factor, WT – wild-type.
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